CrossingBridge Ultra-Short Duration ETF SPC
18.98 USD +0.48 (+2.59%)
At closeJan 27, 2026, 4:00 PM EST
18.70 -0.28 -1.48%
After hours · Jan 27, 4:00 PM ET
18.58 Day range 19.00
21.10 52-week range 21.87
- YTD
- -0.11%
- 1 year
- -10.93%
News
globenewswire.com Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio Allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses SARASOTA, FLA., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or…
globenewswire.com Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system
globenewswire.com Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO)…
globenewswire.com Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio SARASOTA, FL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations…
globenewswire.com Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15 Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the…
defenseworld.net SPC Financial Inc. Sells 970 Shares of NVIDIA Corporation $NVDA SPC Financial Inc. lowered its stake in shares of NVIDIA Corporation (NASDAQ: NVDA) by 3.2% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 29,685 shares…
zacks.com Chipotle to Debut in Asia With SPC Group to Expand Global Footprint CMG partners with SPC Group to debut in South Korea and Singapore in 2026, marking its franchise expansion into Asia.
globenewswire.com Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal Manuscript featured in leading open-access scientific journal Alzheimer's Research & Therapy SARASOTA, FL, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company),…
globenewswire.com Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway SPC-15's intranasal spray formulation meets safety standards for clinical trial development SARASOTA, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company),…
prnewswire.com CrossingBridge Pre-Merger SPAC ETF (Nasdaq: SPC) Designates Cash Creation/Redemption the Default Order Type in Effort to Reduce Trading Volatility and Enhance Liquidity PLEASANTVILLE, N.Y. , July 25, 2025 /PRNewswire/ -- CrossingBridge Advisors, LLC ("CrossingBridge") announced today that it has made a structural change to the CrossingBridge Pre-Merger SPAC ETF…
globenewswire.com Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15 SARASOTA, FL, July 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug…
globenewswire.com Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025 Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved
globenewswire.com Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug…
globenewswire.com Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15 SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug…
globenewswire.com Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting…
globenewswire.com NETSOL signs multi-million-dollar agreement with Sindbad Management SPC in Oman for the implementation of Transcend Finance ENCINO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a global leader in delivering state-of-the-art solutions for the asset finance and leasing industry, has…
globenewswire.com Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment SPC-15 combination treatment shows enhanced efficacy in combating stress-induced psychiatric disorders SARASOTA, FL, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the…